169 related articles for article (PubMed ID: 24386644)
41. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
[TBL] [Abstract][Full Text] [Related]
42. Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro.
Liu YX; Si MM; Lu W; Zhang LX; Zhou CX; Deng SL; Wu HS
J Ethnopharmacol; 2015 May; 166():168-75. PubMed ID: 25792018
[TBL] [Abstract][Full Text] [Related]
43. A bitter herbal medicine Gentiana scabra root extract stimulates glucagon-like peptide-1 secretion and regulates blood glucose in db/db mouse.
Suh HW; Lee KB; Kim KS; Yang HJ; Choi EK; Shin MH; Park YS; Na YC; Ahn KS; Jang YP; Um JY; Jang HJ
J Ethnopharmacol; 2015 Aug; 172():219-26. PubMed ID: 26129938
[TBL] [Abstract][Full Text] [Related]
44. Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
Ji G; Guo Q; Xue Q; Kong R; Wang S; Lei K; Liu R; Wang X
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833999
[TBL] [Abstract][Full Text] [Related]
45. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Nunez DJ; Bush MA; Collins DA; McMullen SL; Gillmor D; Apseloff G; Atiee G; Corsino L; Morrow L; Feldman PL
PLoS One; 2014; 9(4):e92494. PubMed ID: 24699248
[TBL] [Abstract][Full Text] [Related]
46. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
47. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
Flock G; Holland D; Seino Y; Drucker DJ
Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
[TBL] [Abstract][Full Text] [Related]
48. Noninvasive Evaluation of GPR119 Agonist Effects on β-Cell Mass in Diabetic Male Mice Using 111In-Exendin-4 SPECT/CT.
Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Matsumoto K; Inagaki N
Endocrinology; 2019 Dec; 160(12):2959-2968. PubMed ID: 31613319
[TBL] [Abstract][Full Text] [Related]
49. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
50. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways.
Lan H; Lin HV; Wang CF; Wright MJ; Xu S; Kang L; Juhl K; Hedrick JA; Kowalski TJ
Br J Pharmacol; 2012 Apr; 165(8):2799-807. PubMed ID: 22029751
[TBL] [Abstract][Full Text] [Related]
51. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
Zuo Z; Chen M; Shao X; Qian X; Liu X; Zhou X; Xiang J; Deng P; Li Y; Jie H; Liu C; Cen X; Xie Y; Zhao Y
Bioorg Med Chem Lett; 2020 Feb; 30(4):126855. PubMed ID: 31898998
[TBL] [Abstract][Full Text] [Related]
52. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
53. Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
Kim H; Kim M; Oh K; Lee S; Lim S; Lee S; Kim YH; Suh KH; Min KH
Eur J Med Chem; 2023 Oct; 258():115584. PubMed ID: 37356344
[TBL] [Abstract][Full Text] [Related]
54. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766
[TBL] [Abstract][Full Text] [Related]
56. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
57. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
58. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
[TBL] [Abstract][Full Text] [Related]
59. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
60. Hypoglycemic and hypolipidemic effects of total saponins from Stauntonia chinensis in diabetic db/db mice.
Xu J; Wang S; Feng T; Chen Y; Yang G
J Cell Mol Med; 2018 Dec; 22(12):6026-6038. PubMed ID: 30324705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
